65,437 trials
Generalized Pustular Psoriasis
Primary: Time to First Generalized Pustular Psoriasis (GPP) Flare — 37.3; NA; NA; NA weeks — p=0.002
COVID-19
Primary: All-cause Mortality up to Day 60 — 10; 10; 126; 126 Participants — p=0.949
Childhood Obesity
Primary: Changes in Objective Child Physical Activity — 3.3; -0.4; 1.1; 0.0 minutes
Cachexia · Non-Small-Cell Lung Cancer · Pancreatic Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 10; 4 Participants
SARS CoV 2 Infection
Primary: Number of Participants With Undetectable SARS-CoV-2 at PCR at Day 7 After Randomization in the FAS — 7; 4; 0 Participants — p=0.0109
Nonalcoholic Steatohepatitis (NASH)
Primary: Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo. — -7.68; -9.17; -1.54 Percentage of liver fat…
Graft vs Host Disease
Primary: Phase I: MTD (USP hCG) — 2000; 2000; 5000 Pregnyl dosage (USP hCG)
Acute Migraine
Primary: Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose — 19.8; 10.7 Percentage of participants — p=<0.0001
Epilepsy
Primary: Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — 222 Participants
Beta-Thalassemia · Non-transfusion-dependent Thalassemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 7; 3 Participants
Depression · Anxiety · Loneliness
Primary: Patient Health Questionnaire (PHQ-9) — 9.24; 7.29; 7.29; 6.29 score on a scale — p=0.036
Healthy Volunteers
Primary: Number of Participants Who Tolerated All Initiated HYQVIA Infusion — 7; 8; 8; 9 Participants
Healthy Participants
Primary: Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib — 4170; 4340 ng/mL
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Midazolam — 25.3; 28.8 ng/mL
Image Quality
Primary: Image Quality Assessment Method#1: Difference in Likert Scale Before/After Suctioning — 83; 65; 2 images